Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Nov 20 2020

Full Issue

Purdue Was Urged To Pay $14,000 Rebates Per Patient Hurt By Opioids, Documents Show

The suggestion was contained in a proposal made three years ago by McKinsey consultants, STAT reports.

Stat: Purdue Was Advised To Pay Rebates To Insurers For Each Overdose

As Purdue Pharma faced serious challenges to OxyContin sales, the company was advised to consider paying rebates of up to $14,000 to health insurers for each patient who was harmed by its opioid painkiller in order to maintain those crucial business relationships, according to court documents. (Silverman, 11/19)

In other news —

Crain's New York Business: Newer Drugs Improve Health Outcomes, Lower Care Costs: NYC Study

Prescription drug costs have skyrocketed in the U.S. in recent years. But research from Columbia Business School in Morningside Heights found that access to newer medications increases patients' likelihood of taking them, improving health outcomes and decreasing care costs. The research, which was announced this week, from Frank Lichtenberg, professor of healthcare management, found that patients are 2.5% more likely to start and stay on a course of treatment for every 10-year decrease in a drug's time on the market. That's equivalent to a $0.35 reduction in copayment for each day of a patient's therapy. (Henderson, 11/19)

Stat: A Leading AI Researcher Calls For Standards To Ensure Equity And Fairness

A top researcher at the Massachusetts Institute of Technology on Thursday said that artificial intelligence systems developed for medicine must be more transparent and judged against a set of common standards to ensure fairness and equity. (Ross, 11/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF